Table 2 Important features identified by t tests.

From: Serum lipid metabolites predict the efficacy of intravenous immune globulin therapy in patients with pediatric dilated cardiomyopathy

 

Compounds

V

p value

−log10 (p)

FDR

1

PE40:4p

44

0.0020067

2.6975

0.29144

2

GluCer d18:0/24:1

44

0.0020067

2.6975

0.29144

3

PE40:5p

46

0.0027153

2.5662

0.29144

4

GluCer d18:1/16:0

46

0.0036651

2.4359

0.29504

5

PG36:2 (18:0)

54

0.0082127

2.0855

0.44876

6

TAG50:1 (16:0)

181

0.015209

1.8179

0.44876

7

TAG50:1 (18:1)

181.5

0.015888

1.7989

0.44876

8

PE40:6p

59

0.01677

1.7755

0.44876

9

CE-16:1

180.5

0.017695

1.7522

0.44876

10

TAG50:0 (18:0)

179.5

0.019654

1.7065

0.44876

11

PE38:7

60.5

0.019667

1.7063

0.44876

12

PE36:4p

61

0.020742

1.6832

0.44876

13

TAG46:1 (16:1)

178

0.021463

1.6683

0.44876

14

PE40:6 (20:4)

61.5

0.021855

1.6605

0.44876

15

TAG46:2 (16:1)

177

0.02551

1.5933

0.44876

16

PE40:6p (22:6)

63

0.02551

1.5933

0.44876

17

DAG36:1 (18:1/18:0)

176

0.028232

1.5493

0.44876

18

PE38:5p (20:4)

64

0.028232

1.5493

0.44876

19

PE40:4p (20:4)

64

0.028232

1.5493

0.44876

20

PE38:6p

65

0.029751

1.5265

0.44876

21

TAG52:0 (18:0)

174.5

0.032781

1.4844

0.44876

22

TAG48:0 (16:0)

173

0.036637

1.4361

0.44876

23

TAG56:5 (18:2)

67

0.036637

1.4361

0.44876

24

GluCer d18:1/22:0

67

0.037944

1.4209

0.44876

25

LPA16:1

172.5

0.039813

1.4

0.44876

26

TAG56:5 (20:2)

68

0.040543

1.3921

0.44876

27

TAG48:1 (16:0)

172

0.041758

1.3793

0.44876

28

TAG48:1 (16:1)

171.5

0.043784

1.3587

0.44876

29

TAG50:2 (16:1)

171.5

0.043784

1.3587

0.44876

30

LPE18:2

171.5

0.043784

1.3587

0.44876

31

DAG34:1 (16:0/18:1)

170

0.049381

1.3064

0.44876

32

SM18:1/24:0

70

0.049381

1.3064

0.44876

  1. V, the degree of freedom.